Efficacy and safety according to age subgroups in AVEX, a randomized phase III trial of bevacizumab in combination with capecitabine for the first-line treatment of elderly patients with metastatic colorectal cancer.

被引：0
|
作者：
Saunders, Mark P.
Lang, Istvan
Marcuello, Eugenio
Lorusso, Vito
Ocvirk, Janja
Shin, Dongbok
Jonker, Derek J.
Osborne, Stuart
Loeffler, Markus
Waterkamp, Daniel
Cunningham, David
机构：
[1] Christie Hosp NHS Fdn Trust, Withington, England
[2] Natl Inst Oncol, Budapest, Hungary
[3] Hosp St Pau Barcelona, Barcelona, Spain
[4] Vito Fazzi Hosp, Inst Oncol, Bari, Italy
[5] Inst Oncol Ljubljana, Ljubljana, Slovenia
[6] Gachon Univ, Gil Hosp, Dept Internal Med, Inchon, South Korea
[7] Ottawa Hosp, Ctr Canc, Ottawa, ON, Canada
[8] F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland
[9] Royal Marsden Hosp NHS Fdn Trust, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3521
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group
    Kwakman, J. J. M.
    Simkens, L. H. J.
    van Rooijen, J. M.
    van de Wouw, A. J.
    ten Tije, A. J.
    Creemers, G. J. M.
    Hendriks, M. P.
    Los, M.
    van Alphen, R. J.
    Polee, M. B.
    Muller, E. W.
    van der Velden, A. M. T.
    van Voorthuizen, T.
    Koopman, M.
    Mol, L.
    van Werkhoven, E.
    Punt, C. J. A.
    ANNALS OF ONCOLOGY, 2017, 28 (06) : 1288 - 1293
  • [42] The clinical efficacy of FOLFIRI and bevacizumab in combination as first-line therapy of metastatic colorectal cancer
    不详
    CLINICAL COLORECTAL CANCER, 2007, 6 (09) : 621 - 624
  • [43] Phase II Study of Bevacizumab in Combination with Docetaxel and Capecitabine for the First-Line Treatment of Patients with Locally Recurrent or Metastatic Breast Cancer
    Musolino, A.
    Bisagni, G.
    De Matteis, A.
    Nuzzo, F.
    Ardizzoni, A.
    Crino, L.
    Gamucci, T.
    Passalacqua, R.
    Gnoni, R.
    Boni, C.
    CANCER RESEARCH, 2010, 70
  • [44] Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group
    Schmiegel, W.
    Reinacher-Schick, A.
    Arnold, D.
    Kubicka, S.
    Freier, W.
    Dietrich, G.
    Geissler, M.
    Hegewisch-Becker, S.
    Tannapfel, A.
    Pohl, M.
    Hinke, A.
    Schmoll, H. J.
    Graeven, U.
    ANNALS OF ONCOLOGY, 2013, 24 (06) : 1580 - 1587
  • [45] Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial
    Cunningham, David
    Lang, Istvan
    Marcuello, Eugenio
    Lorusso, Vito
    Ocvirk, Janja
    Shin, Dong Bok
    Jonker, Derek
    Osborne, Stuart
    Andre, Niko
    Waterkamp, Daniel
    Saunders, Mark P.
    LANCET ONCOLOGY, 2013, 14 (11): : 1077 - 1085
  • [46] Bevacizumab plus capecitabine and oxaliplatin (XELOX) as first-line treatment for elderly patients with metastatic colorectal cancer (mCRC) suitable for combination chemotherapy: Efficacy and safety findings from the phase II BECOX study (GEMCAD Study Group)
    Feliu, J.
    Salud, A.
    Safont, M. J.
    Garcia-Giron, C.
    Aparicio, J.
    Vera, R.
    Serra, O.
    Casado, E.
    Jorge, M.
    Maurel, J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S553 - S553
  • [47] Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: Results from AVADO
    Pivot, Xavier
    Schneeweiss, Andreas
    Verma, Shailendra
    Thomssen, Christoph
    Passos-Coelho, Jose Luis
    Benedetti, Giovanni
    Ciruelos, Eva
    von Moos, Roger
    Chang, Hong-Tai
    Duenne, Anja-Alexandra
    Miles, David W.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 (16) : 2387 - 2395
  • [48] Efficacy of first-line capecitabine (CAP) ± bevacizumab (BEV) according to risk factors in the RIBBON-1 randomized phase III trial in locally recurrent/metastatic breast cancer (LR/mBC)
    Robert, Nicholas J.
    Dieras, Veronique
    Jackisch, Christian
    Srock, Stefanie
    Freudensprung, Ulrich
    Faoro, Leonardo
    O'Shaughnessy, Joyce
    CANCER RESEARCH, 2014, 74 (19)
  • [49] SAFETY AND EFFICACY OF BEVACIZUMAB PLUS STANDARD FIRST-LINE CHEMOTHERAPY IN PATIENTS WITH METASTATIC COLORECTAL CANCER: FIRST BEAT
    Van Cutsem, E.
    Berry, S.
    Michael, M.
    Kretzschmar, A.
    Rivera, F.
    DiBartolomeo, M.
    Mazier, M.
    Andre, N.
    Cunningham, D.
    ANNALS OF ONCOLOGY, 2008, 19 : 125 - 125
  • [50] Phase III study on efficacy of taxanes plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancer
    Hans-Joachim Lück
    Kristina Lübbe
    Mattea Reinisch
    Nicolai Maass
    Gabriele Feisel-Schwickardi
    Oliver Tomé
    Wolfgang Janni
    Mustafa Aydogdu
    Tanja Neunhöffer
    Angelika Ober
    Bahriye Aktas
    Tjoung-Won Park-Simon
    Claudia Schumacher
    Heinz-Gert Höffkes
    Thomas Illmer
    Harald Wagner
    Keyur Mehta
    Gunter von Minckwitz
    Valentina Nekljudova
    Sibylle Loibl
    Breast Cancer Research and Treatment, 2015, 149 : 141 - 149
12345